Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Transthyretin Amyloidosis Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (ATTR-PN, ATTR-CM)
5.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
5.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
5.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.6. By Company (2022)
5.3. Market Map
5.3.1 By Type
5.3.2 By Therapy
5.3.3 By Disease Type
5.3.4 By Distribution Channel
5.3.5 By Region
6. North America Transthyretin Amyloidosis Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (ATTR-PN, ATTR-CM)
6.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
6.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
6.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Transthyretin Amyloidosis Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Therapy
6.3.1.2.3. By Disease Type
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Transthyretin Amyloidosis Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Therapy
6.3.2.2.3. By Disease Type
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Transthyretin Amyloidosis Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Therapy
6.3.3.2.3. By Disease Type
6.3.3.2.4. By Distribution Channel
7. Europe Transthyretin Amyloidosis Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (ATTR-PN, ATTR-CM)
7.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
7.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
7.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Transthyretin Amyloidosis Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Therapy
7.3.1.2.3. By Disease Type
7.3.1.2.4. By Distribution Channel
7.3.2. Germany Transthyretin Amyloidosis Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Therapy
7.3.2.2.3. By Disease Type
7.3.2.2.4. By Distribution Channel
7.3.3. United Kingdom Transthyretin Amyloidosis Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Therapy
7.3.3.2.3. By Disease Type
7.3.3.2.4. By Distribution Channel
7.3.4. Italy Transthyretin Amyloidosis Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Therapy
7.3.4.2.3. By Disease Type
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Transthyretin Amyloidosis Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Therapy
7.3.5.2.3. By Disease Type
7.3.5.2.4. By Distribution Channel
8. Asia-Pacific Transthyretin Amyloidosis Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (ATTR-PN, ATTR-CM)
8.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
8.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
8.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Transthyretin Amyloidosis Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Therapy
8.3.1.2.3. By Disease Type
8.3.1.2.4. By Distribution Channel
8.3.2. India Transthyretin Amyloidosis Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Therapy
8.3.2.2.3. By Disease Type
8.3.2.2.4. By Distribution Channel
8.3.3. Japan Transthyretin Amyloidosis Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Therapy
8.3.3.2.3. By Disease Type
8.3.3.2.4. By Distribution Channel
8.3.4. South Korea Transthyretin Amyloidosis Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Therapy
8.3.4.2.3. By Disease Type
8.3.4.2.4. By Distribution Channel
8.3.5. Australia Transthyretin Amyloidosis Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Therapy
8.3.5.2.3. By Disease Type
8.3.5.2.4. By Distribution Channel
9. South America Transthyretin Amyloidosis Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type (ATTR-PN, ATTR-CM)
9.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
9.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
9.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Transthyretin Amyloidosis Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Therapy
9.3.1.2.3. By Disease Type
9.3.1.2.4. By Distribution Channel
9.3.2. Argentina Transthyretin Amyloidosis Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Therapy
9.3.2.2.3. By Disease Type
9.3.2.2.4. By Distribution Channel
9.3.3. Colombia Transthyretin Amyloidosis Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Therapy
9.3.3.2.3. By Disease Type
9.3.3.2.4. By Distribution Channel
10. Middle East and Africa Transthyretin Amyloidosis Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (ATTR-PN, ATTR-CM)
10.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
10.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
10.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Transthyretin Amyloidosis Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Therapy
10.3.1.2.3. By Disease Type
10.3.1.2.4. By Distribution Channel
10.3.2. Saudi Arabia Transthyretin Amyloidosis Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Therapy
10.3.2.2.3. By Disease Type
10.3.2.2.4. By Distribution Channel
10.3.3. UAE Transthyretin Amyloidosis Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Therapy
10.3.3.2.3. By Disease Type
10.3.3.2.4. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Global Transthyretin Amyloidosis Treatment Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Pfizer Inc.
15.1.1. Business Overview
15.1.2. Product Offerings
15.1.3. Recent Developments
15.1.4. Financials (As Reported)
15.1.5. Key Personnel
15.1.6. SWOT Analysis
15.2. Johnson & Johnson Services Inc.
15.3. Ionis Pharmaceuticals Inc.
15.4. Alnylam Pharmaceuticals Inc.
15.5. BridgeBio Pharma Inc.
15.6. Bristol-Myers Squibb Company.
15.7. Acrotech Biopharma.
15.8. AstraZeneca Plc.
15.9. SOM Biotech.
16. Strategic Recommendations